We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aduhelm Gets Thumbs Down From EMA as Biogen Plans U.S. Confirmatory Study
Aduhelm Gets Thumbs Down From EMA as Biogen Plans U.S. Confirmatory Study
In another huge blow to Biogen’s controversial Alzheimer’s blockbuster, the European Medicines Agency (EMA) has declined to approve Aduhelm (aducanumab), saying the data don’t support a strong clinical benefit and studies did not show that the medicine was sufficiently safe.